Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Clin Toxicol (Phila) ; 51(3): 134-9, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23406298

ABSTRACT

CONTEXT: An update of the first position paper on ipecac syrup from 1997 was published by the American Academy of Clinical Toxicology and the European Association of Poison Centres and Clinical Toxicologists in 2004. The aims of this paper are to briefly summarize the content of the 2004 Position Paper and to present any new data. METHODS: A systematic review of the literature from the year 2003 forward. RESULTS: The literature search yielded a limited number of meaningful articles, and there remains no convincing evidence from clinical studies that ipecac improves the outcome of poisoned patients. Furthermore, the availability of ipecac is rapidly diminishing. CONCLUSIONS: The routine administration of ipecac at the site of ingestion or in the emergency department should definitely be avoided. Ipecac may delay the administration or reduce the effectiveness of activated charcoal, oral antidotes, and whole bowel irrigation. There is not sufficient evidence to warrant any change in the previous ipecac position papers. There are, however, insufficient data to support or exclude ipecac administration soon after ingestion of some specific poisons in rare situations.


Subject(s)
Decontamination/standards , Drug Overdose/drug therapy , Emetics/therapeutic use , Ipecac/therapeutic use , Decontamination/methods , Emetics/adverse effects , Humans , Ipecac/adverse effects , Vomiting/chemically induced
2.
J Affect Disord ; 115(3): 386-94, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19027962

ABSTRACT

BACKGROUND: Optimal parameters of rTMS for antidepressant efficacy in general, or within patients, have not been adequately delineated. METHODS: Using a double-blind, sham-controlled, cross-over design, 22 adult patients with treatment refractory major depression (n=9; bipolar disorder, depressed phase) were randomized to active rTMS (20-Hz or 1-Hz) or sham rTMS conditions and given 5 rTMS treatments per week for two weeks. Repetitive TMS was administered at 100% of motor threshold for 1600 pulses over the left prefrontal cortex using a figure-eight coil. Patients initially randomized to sham rTMS were then exposed to two weeks of active rTMS with each frequency under blinded conditions. Those who received active 20-Hz and 1-Hz rTMS were crossed over to the opposite frequency for two weeks. Improvement in Hamilton Depression ratings were assessed after each two-week treatment phase. PET imaging was used to evaluate the patient's baseline absolute regional cerebral activity (blood flow and metabolism) as potential predictor of clinical response. RESULTS: Changes in depression severity on 1-Hz and 20-Hz rTMS were inversely correlated. PET scans with baseline hypoperfusion (but not hypometabolism) were associated with better improvement on 20-Hz rTMS as predicted. LIMITATIONS: The magnitude of the clinical change with either frequency at 100% motor threshold was not robust, and larger studies with higher intensities of rTMS for longer durations of time should be explored. CONCLUSIONS: High and low frequency rTMS exerts differential effects on depressed mood within individual subjects. The brain activity predictors and correlates of an optimal antidepressant response to rTMS remain to be better defined.


Subject(s)
Bipolar Disorder/therapy , Brain/blood supply , Depression/therapy , Depressive Disorder, Major/therapy , Electric Stimulation Therapy/methods , Positron-Emission Tomography , Adult , Bipolar Disorder/diagnostic imaging , Bipolar Disorder/physiopathology , Brain/diagnostic imaging , Brain/physiopathology , Cross-Over Studies , Depression/diagnostic imaging , Depression/physiopathology , Depressive Disorder, Major/diagnostic imaging , Depressive Disorder, Major/physiopathology , Dose-Response Relationship, Radiation , Double-Blind Method , Electromagnetic Phenomena , Female , Fluorodeoxyglucose F18/metabolism , Humans , Magnetoencephalography , Male , Positron-Emission Tomography/methods , Prefrontal Cortex/blood supply , Psychiatric Status Rating Scales , Research Design , Severity of Illness Index , Treatment Outcome
3.
J Toxicol Clin Toxicol ; 39(5): 433-8, 2001.
Article in English | MEDLINE | ID: mdl-11545231

ABSTRACT

BACKGROUND: The purpose of this study was to determine the extent to which poison center triage guidelines influence healthcare facility referral rates for acute, unintentional acetaminophen-only poisoning and acute, unintentional adult formulation iron poisoning. METHODS: Managers of US poison centers were interviewed by telephone to determine their center's triage threshold value (mg/kg) for acute iron and acute acetaminophen poisoning in 1997. Triage threshold values and healthcare facility referral rates were fit to a univariate logistic regression model for acetaminophen and iron using maximum likelihood estimation. RESULTS: Triage threshold values ranged from 120-201 mg/kg (acetaminophen) and 16-61 mg/kg (iron). Referral rates ranged from 3.1% to 24% (acetaminophen) and 3.7% to 46.7% (iron). There was a statistically significant inverse relationship between the triage value and the referral rate for acetaminophen (p < 0.001) and iron (p = 0.0013). The model explained 31.7% of the referral variation for acetaminophen but only 4.1% of the variation for iron. CONCLUSION: There is great variability in poison center triage values and referral rates for iron and acetaminophen poisoning. Guidelines can account for a meaningful proportion of referral variation. Their influence appears to be substance dependent. These data suggest that efforts to determine and utilize the highest, safe, triage threshold value could substantially decrease healthcare costs for poisonings as long as patient medical outcomes are not compromised.


Subject(s)
Guidelines as Topic , Poison Control Centers/standards , Poisoning/therapy , Referral and Consultation , Triage/standards , Acetaminophen/poisoning , Adult , Analgesics, Non-Narcotic/poisoning , Dietary Supplements/poisoning , Humans , Iron/poisoning , New Mexico
4.
Biol Psychiatry ; 49(2): 97-109, 2001 Jan 15.
Article in English | MEDLINE | ID: mdl-11164756

ABSTRACT

BACKGROUND: Functional brain imaging studies in unipolar and secondary depression have generally found decreased prefrontal cortical activity, but in bipolar disorders findings have been more variable. METHODS: Forty-three medication-free, treatment-resistant, predominantly rapid-cycling bipolar disorder patients and 43 age- and gender-matched healthy control subjects had cerebral glucose metabolism assessed using positron emission tomography and fluorine-18-deoxyglucose. RESULTS: Depressed bipolar disorder patients compared to control subjects had decreased global, absolute prefrontal and anterior paralimbic cortical, and increased normalized subcortical (ventral striatum, thalamus, right amygdala) metabolism. Degree of depression correlated negatively with absolute prefrontal and paralimbic cortical, and positively with normalized anterior paralimbic subcortical metabolism. Increased normalized cerebello-posterior cortical metabolism was seen in all patient subgroups compared to control subjects, independent of mood state, disorder subtype, or cycle frequency. CONCLUSIONS: In bipolar depression, we observed a pattern of prefrontal hypometabolism, consistent with observations in primary unipolar and secondary depression, suggesting this is part of a common neural substrate for depression independent of etiology. In contrast, the cerebello-posterior cortical normalized hypermetabolism seen in all bipolar subgroups (including euthymic) suggests a possible congenital or acquired trait abnormality. The degree to which these findings in treatment-resistant, predominantly rapid-cycling patients pertain to community samples remains to be established.


Subject(s)
Affect/physiology , Bipolar Disorder/metabolism , Brain Chemistry/physiology , Glucose/metabolism , Acoustic Stimulation , Adult , Aged , Bipolar Disorder/drug therapy , Discrimination, Psychological/physiology , Drug Resistance , Female , Fluorodeoxyglucose F18 , Humans , Image Processing, Computer-Assisted , Male , Middle Aged , Psychiatric Status Rating Scales , Radiopharmaceuticals
6.
J Toxicol Clin Toxicol ; 24(1): 69-76, 1986.
Article in English | MEDLINE | ID: mdl-2871196

ABSTRACT

A 68-year-old male attempted suicide by drinking three ounces of concentrated Cygon 2-E (23.4% dimethoate). He was immediately brought to the hospital, responded to standard treatment (ipecac, activated charcoal, 2-PAM, atropine), and was transferred from the ICU to general care 24 hours after the exposure. Within eight hours of the transfer, he relapsed and was moved to the CCU, where he required five milligrams of atropine every ten minutes for 24 hours, before being started on an atropine drip. The patient was maintained on the atropine drip (0.5-2.4 mg/kg/hr) for five weeks. He required a total atropine dose of 30 grams, the largest amount ever reported to have been administered to a human. Although S-ChE activities gradually increased they were not found to be helpful in determining when the drip could be safely stopped. Control of hypersecretions served as the best monitoring parameter for titration of the drip rate. The patient recovered completely with the exception of a detectable sensorineural hearing deficit, a slight, nonspecific personality change, and minimal spastic rigidity thought to be secondary to several anoxic episodes.


Subject(s)
Atropine/therapeutic use , Dimethoate/poisoning , Aged , Charcoal/therapeutic use , Cholinesterases/blood , Humans , Infusions, Parenteral , Ipecac/therapeutic use , Male , Suicide, Attempted
SELECTION OF CITATIONS
SEARCH DETAIL